Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 6/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17796258 | 0.82 | TSHR (0.48) | TSHRARCYP11B2ALDH1A1KDM4E | |
| SCHEMBL3026622 | 0.78 | MAOB (0.42) | ALDH1A1KDM4EUSP2TRPV4 | |
| SCHEMBL277588 | 0.76 | TSHR (0.52) | TSHRAREGLN2ALDH1A1 | |
| SCHEMBL13001686 | 0.76 | TSHR (0.52) | TSHRAREGLN2CYP11B2CYP11B1 | |
| SCHEMBL30361887 | 0.76 | TSHR (0.52) | TSHRAREGLN2ALDH1A1 | |
| SCHEMBL12317792 | 0.74 | TSHR (0.50) | TSHRS1PR3ARMRGPRX4EGLN2 | |
| SCHEMBL393190 | 0.74 | TSHR (0.50) | TSHRS1PR3AREGLN2CYP11B2 | |
| SCHEMBL518867 | 0.73 | TRPV4 (0.57) | S1PR3ARCYP11B2TRPV4 | |
| SCHEMBL21698055 | 0.73 | TSHR (0.48) | TSHRS1PR3ARMRGPRX4EGLN2 | |
| SCHEMBL290236 | 0.73 | TSHR (0.48) | TSHRS1PR3EGLN2S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3029030-B1 | TETRAZOLINONE COMPOUND, AND USE THEREFOR | SUMITOMO CHEMICAL CO (JP) | 2019-09-04 | — | — | EP | disclosed |
| US-9512090-B2 | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-12-06 | — | — | US | disclosed |
| US-20160159755-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
| EP-3029030-A1 | TETRAZOLINONE COMPOUND, AND USE THEREFOR | Sumitomo Chemical Company, Limited (JP) | 2016-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159755-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | CYP1A1, CASP1, TCOF1 | TSHR 51/4885S1PR3 2597/4885AR 988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.